- Home
- CAPR vs HVT Comparison
CAPR vs HVT Comparison
Compare CAPR & HVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- HVT
- Stock Information
- Founded
- CAPR 2005
- HVT 1885
- Country
- CAPR United States
- HVT United States
- Employees
- CAPR N/A
- HVT N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- HVT Other Specialty Stores
- Sector
- CAPR Health Care
- HVT Consumer Discretionary
- Exchange
- CAPR Nasdaq
- HVT Nasdaq
- Market Cap
- CAPR 324.6M
- HVT 329.5M
- IPO Year
- CAPR N/A
- HVT N/A
- Fundamental
- Price
- CAPR $6.36
- HVT $22.74
- Analyst Decision
- CAPR Strong Buy
- HVT
- Analyst Count
- CAPR 8
- HVT 0
- Target Price
- CAPR $24.75
- HVT N/A
- AVG Volume (30 Days)
- CAPR 1.2M
- HVT 108.9K
- Earning Date
- CAPR 11-12-2025
- HVT 10-29-2025
- Dividend Yield
- CAPR N/A
- HVT 5.34%
- EPS Growth
- CAPR N/A
- HVT N/A
- EPS
- CAPR N/A
- HVT 1.17
- Revenue
- CAPR $13,392,150.00
- HVT $722,858,000.00
- Revenue This Year
- CAPR N/A
- HVT $3.69
- Revenue Next Year
- CAPR $6,061.53
- HVT $8.33
- P/E Ratio
- CAPR N/A
- HVT $20.45
- Revenue Growth
- CAPR N/A
- HVT N/A
- 52 Week Low
- CAPR $4.05
- HVT $17.01
- 52 Week High
- CAPR $23.40
- HVT $28.53
- Technical
- Relative Strength Index (RSI)
- CAPR 42.32
- HVT 50.12
- Support Level
- CAPR $6.05
- HVT $23.06
- Resistance Level
- CAPR $6.62
- HVT $24.00
- Average True Range (ATR)
- CAPR 0.39
- HVT 0.63
- MACD
- CAPR 0.05
- HVT -0.02
- Stochastic Oscillator
- CAPR 47.89
- HVT 29.46
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About HVT Haverty Furniture Companies Inc.
Haverty Furniture Companies Inc is a specialty retailer of residential furniture and accessories. It provides various products such as Sofa Tables, Sleepers, End Tables, Cocktail Tables, Accent Pieces, Display Cabinets, Wall Decor, floral and Tress, and other related products. The company operates in the Southern and Midwestern U.S. All its activities are encompassed in its Merchandise division. The company derives the majority of its revenue from its upholstery products and, secondarily, from bedroom furniture.